<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><object-id pub-id-type="doi">10.7554/eLife.46258.013</object-id><label>Table 2.</label><caption><title>mAbs to accessible ECLs do not inhibit essential function of LptD.</title></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th/><th colspan="3">Growth inhibitory &#945;-LptD mAbs*</th></tr><tr><th>Antigen</th><th>Host</th><th>Clones</th><th>K-12<sup>&#8224;</sup></th><th>&#916;<italic>waaD</italic><sup>&#8225;</sup></th><th>&#916;<italic>waaD</italic>&#160;+&#160;Rif.<sup>&#167;</sup></th></tr></thead><tbody><tr><td>Linear and cyclic LptD peptides</td><td>SD Rats</td><td>576</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Purified LptDE</td><td>Mice</td><td>3360</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Purified LptDE</td><td>SD Rats</td><td>2400</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Cells and purified LptDE</td><td>SD Rats</td><td>1494</td><td>0</td><td>0</td><td>0</td></tr></tbody></table><table-wrap-foot><fn><p>*For each antibody campaign, bacterial growth was measured (OD<sub>600</sub>) for <italic>E. coli</italic> &#916;<italic>waaD</italic> and <italic>E. coli</italic> K-12 after treatment with each antibody at 10 &#181;g/mL for 4 hr. Growth inhibition was calculated as a percentage of growth compared to an untreated control. 50% growth inhibition was considered positive.</p><p><sup>&#8224;</sup>WT (wild-type) is <italic>E. coli</italic> K-12.</p></fn><fn><p><sup>&#8225;</sup>&#916;<italic>waaD</italic> is an <italic>E. coli</italic> &#916;<italic>waaD</italic>.</p><p><sup>&#167;</sup>&#916;<italic>waaD</italic>&#160;+&#160;Rif. is <italic>E. coli</italic> &#916;<italic>waaD</italic> grown in the presence sub-inhibitory rifampicin</p></fn></table-wrap-foot></table-wrap>